Hematopoietic Stem Cells Transplantation Market Outlook:
Hematopoietic Stem Cells Transplantation Market size was valued at USD 3.47 billion in 2025 and is set to exceed USD 10.21 billion by 2035, expanding at over 11.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of hematopoietic stem cells transplantation is evaluated at USD 3.83 billion.
The reason behind the growth is impelled by the rising prevalence of leukemia. Hematopoietic stem cell transplantation can be used to treat certain cancers, including leukemia, as stem cells aid in immune system restoration and the stimulation of new bone marrow development that may benefit patients to regenerate healthy bone marrow. In 2020, there were more than 474,510 new cases of leukemia reported globally.
The growing advancements in stem cell transplantation technology are believed to fuel the market growth. For instance, in February 2023, Lund University in Sweden discovered that stem cells have shown promise in treating the inflammation that underlies heart failure as it was found that patients receiving the treatment had more than 55% lower risk of heart attack or stroke, and the benefits rose to over 70% in patients with high inflammation since the treatment may decrease plaque instability.
Key Hematopoietic Stem Cells Transplantation Market Insights Summary:
Regional Highlights:
- North America is forecast to command 40% share by 2035 in the hematopoietic stem cells transplantation market, attributed to the presence of major key players and rising mergers and acquisitions fostering advanced treatment development.
- APAC is anticipated to emerge as the second-largest regional market by 2035, fueled by expanding medical tourism and the availability of advanced yet cost-effective stem cell transplant facilities.
Segment Insights:
- The autologous segment is projected to capture 58% share by 2035 in the hematopoietic stem cells transplantation market, propelled by the rising prevalence of cancer.
- The blood stem cell transplant segment is anticipated to secure a notable share by 2035, driven by increasing adoption of peripheral blood stem cells, cord blood, and bone marrow transplantation procedures.
Key Growth Trends:
- Rising Elderly Population
- Growing Incidence of Lymphoma
Major Challenges:
- Adverse Effected Resulting From Hematopoietic Stem Cells Transplantation
- High Cost of Hematopoietic Stem Cells Transplantation Treatment Owing to the Complexity of the Procedure
Key Players: Duraflame Inc., Timber Charcoal Company Co. LLC, Gryfskand sp. z o.o, Kingsford Products Company, Royal Oak Enterprises, LLC, Weber-Stephen Products LLC, Snesmi Techno Pvt Ltd, Sun Company, Halogen Supply Co. Inc., Vale S.A.
Global Hematopoietic Stem Cells Transplantation Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 3.47 billion
- 2026 Market Size: USD 3.83 billion
- Projected Market Size: USD 10.21 billion by 2035
- Growth Forecasts: 11.4% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (40% Share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, Germany, Japan, United Kingdom
- Emerging Countries: China, India, Japan, South Korea, Brazil
Last updated on : 25 February, 2026
Hematopoietic Stem Cells Transplantation Market - Growth Drivers and Challenges
Growth Drivers
- Rising Elderly Population – Hematopoietic cell transplant (HCT) is increasingly being referred by physicians to older adults for the treatment of malignancies since age is no longer seen as a complete barrier to hematopoietic stem cell transplantation (HSCT). As per the World Health Organization, the worldwide geriatric population was over 524 million in 2010 and this number is expected to cross 2 billion by 2050.
- Growing Incidence of Lymphoma- Stem cell transplantation is frequently used to treat blood malignancies such as Hodgkin lymphoma and non-Hodgkin lymphoma by replacing damaged bone marrow cells with healthy stem cells.
- Increasing Prevalence of Sickle Cell Disorders- The sole treatment for individuals with sickle cell disease (SCD) is hematopoietic stem cell transplantation (HSCT) since it entails transferring healthy cells from a sibling or sister who qualifies to replace the aberrant stem cells that are present in the bone marrow.
- Surging Research & Development Activities- For instance, in 2020, Gamida Cell announced that it had completed enrollment in the Phase 3 clinical trial of its hematopoietic stem cell product.
Challenges
- Adverse Effected Resulting From Hematopoietic Stem Cells Transplantation - Numerous adverse effects of an HSCT transplant resemble those that are frequently experienced after receiving radiation and chemotherapy including greater risk of infection, relapse in illness, death from CMV infection, and graft-versus-host disease (GVHD) which may result from age, baseline performance condition, the source of the stem cell transplant, the kind and severity of the preparative regimen, and many other factors. Moreover, patients who had severe marrow fibrosis before transplantation may also experience graft failure which is frequently linked to a cancer recurrence as the leukemic cells may prevent the transplanted cells from growing.
- High Cost of Hematopoietic Stem Cells Transplantation Treatment Owing to the Complexity of the Procedure
- Limited Availability of Matched Donors As it Involves Intricate Tissue Typing and HLA Matching
Hematopoietic Stem Cells Transplantation Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
11.4% |
|
Base Year Market Size (2025) |
USD 3.47 billion |
|
Forecast Year Market Size (2035) |
USD 10.21 billion |
|
Regional Scope |
|
Hematopoietic Stem Cells Transplantation Market Segmentation:
Transplant Type Segment Analysis
The autologous segment is estimated to account for 58% share of the global hematopoietic stem cells transplantation market in the coming years owing to the rising prevalence of cancer. The incidence of cancer increases sharply with age, most likely because certain malignancies have accumulating risks that climb with age. The primary driver of the general increase in cancer risk is our advancing age, adoption of a Western lifestyle, poor eating practices, dairy products, processed foods, food additives, non-vegetarian diets, chemical pollution, constipation, and physical inactivity. This has significantly led to an increase in the demand for autologous hematopoietic stem cell transplantation as it is used to treat certain types of cancer.
An autologous stem cell transplant also known as autologous bone marrow transplant replaces malfunctioning bone marrow with healthy blood stem cells from within the body that are utilized for patients whose illnesses require heavy dosages of radiation and chemotherapy whereby the damaged bone marrow is partially restored with the use of an autologous stem cell transplant. According to estimates, there were more than 609,810 cancer deaths and over 1,957,310 new cancer cases in the US in 2023.
Application Segment Analysis
Hematopoietic stem cells transplantation market from the blood stem cell transplant segment is set to garner a notable share shortly. A blood stem cell transplant is a surgical technique that involves the transplantation of peripheral blood stem cells, cord blood, and bone marrow to introduce healthy blood-forming cells from a donor into the patient's circulation, where they start to proliferate and produce platelets, red blood cells, and white blood cells.
End-User Segment Analysis
The hospitals segment is anticipated to gain a robust market share of 54% during the forecast timeframe. The treatment for hematopoietic stem cell transplantation is usually done in hospitals as they offer a whole spectrum of transplant services and the availability of skilled medical professionals.
Our in-depth analysis of the global hematopoietic stem cells transplantation market includes the following segments:
|
Transplant Type |
|
|
Application |
|
|
Disease Indication |
|
|
End-User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Hematopoietic Stem Cells Transplantation Market - Regional Analysis
North American Market Insights
Hematopoietic stem cells transplantation market in North America is predicted to account for the largest share of 40% by 2035 impelled by the presence of major key players in the region. This has led to increasing mergers and acquisitions in the region which has led to the development of advanced hematopoietic stem cell transplantation treatment. For instance, in 2021, Avalon GloboCare Corp. acquired Hebei Senlang Biotechnology Co. Ltd. to create a strong pipeline that comprises over 14 universal, autologous, "off-the-shelf" CAR-T and CAR-γδT cell therapy candidates to enhance cutting-edge cell/gene engineering and exclusive cell expansion knowledge with exceptional therapeutic efficacy and safety profile.
APAC Market Insights
The APAC hematopoietic stem cells transplantation market is estimated to be the second largest, during the forecast timeframe led by growing medical tourism. India is becoming a major destination for medical tourism, providing people from all over the world with high-quality healthcare at reasonable prices, and cutting-edge medical facilities. India has become a popular location for people undergoing stem cell transplants aided by the availability of cutting-edge facilities, skilled medical personnel, and cutting-edge technology that attracts medical tourists who may not be able to pay or obtain them in their native countries.
Hematopoietic Stem Cells Transplantation Market Players:
- Lonza Group Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Escape Therapeutics, Inc.
- Regen BioPharma, Inc.
- ThermoGenesis Holdings, Inc.
- CSG-BIO Company, Inc. (CellSave)
- CBR Systems, Inc.
- Pluristem Inc.
- Global Cord Blood Corporation
- ViaCord, LLC
- Cynata Therapeutics Limited
Recent Developments
- Lonza Group announced to increase the number of human stem cells it offers by supplying big batch sizes of CD34+ hematopoietic stem cells from human cord blood to expand cohorts for greater capacity and easier HLA-matched model development.
- Regen BioPharma, Inc. Announced the introduction of a novel immunotherapy approach using chimeric antigen receptor (CAR) natural killer (NK), macrophage (M), and T cells (T) to overcome the challenges associated with T cell fatigue in existing strategies and enable these cell therapies to successfully target solid tumors.
- Report ID: 3937
- Published Date: Feb 25, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Hematopoietic Stem Cells Transplantation Market Report Scope
Free Sample includes current and historical market size, growth trends, regional charts & tables, company profiles, segment-wise forecasts, and more.
Connect with our Expert
Copyright @ 2026 Research Nester. All Rights Reserved.
